January 2025 SCRI Release Copied
SCRI Trials and Trial Regimen Updates
The following updates were completed between Dec. 13, 2024, through Jan. 24, 2025. Sarah Cannon Research Institute now manages all SCRI/USOR trials and trial regimens. For questions about these trials and regimens, please contact SCRIiKMEMRedits@McKesson.com.
New Builds Completed
| Study Number | Notes for New Build |
| 24144 | USOR 24144 MM 189 Phase 1b Arm C ABBV-383 Q28D |
| 24070 | USOR 24070 AML 73 Phase 1b APVO436 + Venetoclax + Azacitidine Q28D |
| 24018 | USOR 24018 LUN 565 Phase 3 Randomized Adagrasib Q21D
USOR 24018 LUN 565 Phase 3 Randomized Divarasib Q21D USOR 24018 LUN 565 Phase 3 Randomized Sotorasib Q21D |
| 23308 | USOR 23308 BRE 437 Phase 2 Alisertib + Endocrine Therapy Q28D |
| 21181 | USOR 21181 GU 200 Phase 2b Enzalutamide Lead In Dosing 21D
USOR 21181 GU 200 Phase 2b Enzalutamide Monotherapy Q28D USOR 21181 GU 200 Phase 2b ZEN003694 + Enzalutamide Q28D |
| 23122 | USOR 23122 CLL 56 Phase 3 Randomized Acalabrutinib Q28D
USOR 23122 CLL 56 Phase 3 Randomized Ibrutinib Q28D USOR 23122 CLL 56 Phase 3 Randomized Nemtabrutinib Q28D |
| 24169 | USOR 24169 MULTI 88 Phase 2 Zanidatamab Q21D |
| 23328 | USOR 23328 MULTI 87 Phase 2 Zongertinib Q21D |
| 24093 | USOR 24093 GI 379 Phase 3 Arm A T-DXd (Enhertu) + Rilvegostomig Q21D
USOR 24093 GI 379 Phase 3 Arm B T-DXd (Enhertu) Q21D USOR 24093 GI 379 Phase 3 Arm C Durvalumab + Gemcitabine D1,8 + Cisplatin D1,8 Q21D (Cycle 1-8) USOR 24093 GI 379 Phase 3 Arm C Durvalumab Q28D (Cycle 9+) USOR 24093 GI 379 Phase 3 Safety Run-In T-DXd (Enhertu) + Rilvegostomig Q21D |
| 24145 | USOR 24145 MM 158 Phase 3 Stage 2 Arm A Mezigdomide + Bortezomib + Dexamethasone Q21D
USOR 24145 MM 158 Phase 3 Stage 2 Arm B Pomalidomide + Bortezomib + Dexamethasone Q21D |
Updated Reference Information
| Study Number | Updated Reference Information | Updated Regimen Instructions | Other Changes |
| 23129 | Version 4.0: 24 Oct 2024 | Updated infusion instructions | n/a |
| 18283 | Amendment 12: 10 May 2024 | Updated infusion instructions | Updated pre-med selection |
| 23080 | Version 3.0: 26 Sep 2024 | Updated drug prep instructions | Weight-based calculation |
| 22159 | Version 7.1: 20 June 2024 | n/a | n/a |
| 23074 | Amendment 03: 05 August 2024 | n/a | n/a |
| 22242 | Version 5.0: 22 July 2024 | n/a | n/a |
| 22258 | Amendment 3: 23 Sep 2024 | Weight-based dosing | n/a |
| 23180 | n/a | Updated drug preparation instructions | n/a |
| 24065 | Version 5: 27 June 2024 | Updated treatment duration wording | n/a |
| 23156 | Version 4.0: 01 Oct 2024 | n/a | n/a |
| 21533 | Version 5: 07 Feb 2024 | n/a | Added sub-study arms |
| 23289 | Version 2.0: 20 Aug 2024 | n/a | NA |
| 20270 | Version 9.0: 24 Sep 2024 | n/a | n/a |
| 23031 | Version 4: 23 Sep 2024 | Added drug preparation instructions |
|
| 23225 | Amendment 1.0: 20 August 2024 | n/a | n/a |
| 23337 | Version 2: 18 Oct 2024 | n/a | n/a |
| 23065 | Version 6.0: 13SEP2024 | n/a | n/a |
| 23335 | PCL 12Nov2024 | Updated Infusion time wording | n/a |
| 22187 | Amendment 2: 23 Sep 2024 | n/a | Updated drug observation wording |
| 23304 | Version 9.0: 26 Sep 2024 | n/a | Updated additional medications (pegfilgrastim) |
| 22297 | n/a | Added preparation instructions | n/a |
| 23340 | n/a | Added infusion/preparation instructions | n/a |
| 23120 | Version 8.0: 11 Oct 2024 | Updated preparation instructions | Updated premedication schedule |
| 22067 | Amendment 5.3 26 Nov 2024 | n/a | n/a |
| 23189 | Version 5.0: 02 Sep 2024 | Added weight-based dosing instructions | Added regimen comments |
| 23236 | Amendment 2: 26 Aug 2024 | n/a | n/a |
| 22181 | Amendment 03: 29 Sep 2024 | n/a | n/a |
| 23172 | Amendment 2: 07 May 2024 | n/a | Updated drug procurement |
| 21225 | Amendment 6: 06 Sep 2024 | Added preparation instructions |
|
| 22298 | n/a | Added preparation instructions | n/a |
| 24018 | n/a | Updated dosing instructions | n/a |